tradingkey.logo

Trinity Biotech PLC

TRIB

0.818USD

+0.113+16.11%
Close 08/04, 16:00ETQuotes delayed by 15 min
6.78MMarket Cap
LossP/E TTM

Trinity Biotech PLC

0.818

+0.113+16.11%
More Details of Trinity Biotech PLC Company
Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.
Company Info
Ticker SymbolTRIB
Company nameTrinity Biotech PLC
IPO dateOct 21, 1992
CEOMr. John Gillard
Number of employees- -
Security typeDepository Receipt
Fiscal year-endOct 21
AddressIda Business Park, Bray, Co Wicklow
CityDUBLIN
Stock exchangeNASDAQ Global Select Consolidated
CountryIreland
Postal code18
Phone01135312955111
Websitehttps://www.trinitybiotech.com/
Ticker SymbolTRIB
IPO dateOct 21, 1992
CEOMr. John Gillard
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Matthew Wictome
Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Eric Ribner
Eric Ribner
Investors Relations
Investors Relations
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Matthew Wictome
Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Eric Ribner
Eric Ribner
Investors Relations
Investors Relations
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
By RegionUSD
Name
Revenue
Proportion
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MiCo IVD Holdings, LLC
12.01%
Hunter Associates Investment Management LLC
2.01%
Whitefort Capital Management, LP
0.44%
Renaissance Technologies LLC
0.41%
HRT Financial LP
0.36%
Other
84.77%
Shareholders
Shareholders
Proportion
MiCo IVD Holdings, LLC
12.01%
Hunter Associates Investment Management LLC
2.01%
Whitefort Capital Management, LP
0.44%
Renaissance Technologies LLC
0.41%
HRT Financial LP
0.36%
Other
84.77%
Shareholder Types
Shareholders
Proportion
Corporation
12.01%
Investment Advisor
2.97%
Hedge Fund
1.25%
Investment Advisor/Hedge Fund
0.27%
Research Firm
0.15%
Other
83.35%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
50
3.10M
16.65%
-2.10M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
2023Q2
47
3.98M
52.08%
+190.03K
2023Q1
47
3.51M
70.22%
+1.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
MiCo IVD Holdings, LLC
2.24M
12.01%
--
--
Dec 17, 2024
Hunter Associates Investment Management LLC
375.11K
2.01%
-3.48K
-0.92%
Mar 31, 2025
Whitefort Capital Management, LP
81.90K
0.44%
--
--
Mar 31, 2025
Renaissance Technologies LLC
76.67K
0.41%
-112.39K
-59.45%
Mar 31, 2025
HRT Financial LP
66.24K
0.36%
+66.24K
--
Mar 31, 2025
Citadel Advisors LLC
41.54K
0.22%
+41.54K
--
Mar 31, 2025
Highbridge Capital Management, LLC
33.75K
0.18%
+33.75K
--
Mar 31, 2024
Two Sigma Investments, LP
32.62K
0.18%
+32.62K
--
Mar 31, 2025
Moss Adams Wealth Advisors LLC
25.67K
0.14%
--
--
Mar 31, 2025
Raymond James & Associates, Inc.
25.35K
0.14%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 13, 2024
Merger
5<1
Feb 13, 2024
Merger
5<1
Feb 13, 2024
Merger
5<1
Feb 13, 2024
Merger
5<1
Date
Type
Ratio
Feb 13, 2024
Merger
5<1
Feb 13, 2024
Merger
5<1
Feb 13, 2024
Merger
5<1
Feb 13, 2024
Merger
5<1
KeyAI